Pharsight

Juxtapid generic

Juxtapid is an oral medication used in the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia. Owned by Amryt, this drug contains the active ingredient lomitapide mesylate. Juxtapid first hit the markets on December 21, 2012, and holds a total of 8 patents, none of which have expired yet.

When will Juxtapid generic be available?

The generic variants of Juxtapid can be anticipated to arrive after 19th August, 2027. This is the expiry date of its last patent. Until then, no generic versions of Juxtapid will be legally available on the market.

Juxtapid uses

Juxtapid, containing lomitapide mesylate, is specifically designed for treating hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia. It is available in capsule form and utilizes a step-wise increasing dosing regimen to effectively lower cholesterol and lipid levels in the blood.

Juxtapid patent expiration

Juxtapid holds a total of 8 patents all focused on methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects. None of these patents have expired yet. The last patent, with the number US7932268, will expire on 19th August, 2027. Post this date, the market can expect the release of Juxtapid's generic versions. Below are the details of the patent:

EPO Oppostions filed on Juxtapid

Litigations filed on Juxtapid

Juxtapid dosage

Want to ask something?